New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
06:24 EDTPGNXProgenics upgraded to Buy from Hold at Needham
Needham upgraded Progenics Pharmaceuticals with an $8 price target citing the company's positive Phase 2 data for prostate cancer.
News For PGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
09:20 EDTPGNXValeant and Progenics announces submission of NDA to FDA for RELISTOR
Valeant Pharmaceuticals International (VRX) and Progenics Pharmaceuticals (PGNX) announced that Valeant submitted a New Drug Application, or NDA, to the FDA for RELISTOR, or methylnaltrexone bromide, Tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use